Search results for "ergot"

showing 10 items of 24 documents

Repurposing of Bromocriptine for Cancer Therapy

2018

Bromocriptine is an ergot alkaloid and dopamine D2 receptor agonist used to treat Parkinson’s disease, acromegaly, hyperprolactinemia, and galactorrhea, and more recently diabetes mellitus. The drug is also active against pituitary hormone-dependent tumors (prolactinomas and growth-hormone producing adenomas). We investigated, whether bromocriptine also inhibits hormone-independent and multidrug-resistant (MDR) tumors. We found that bromocriptine was cytotoxic towards drug-sensitive CCRF-CEM, multidrug-resistant CEM/ADR5000 leukemic cells as well as wild-type or multidrug-resistant ABCB5-transfected HEK293 cell lines, but not sensitive or BCRP-transfected multidrug-resistant MDA-MB-231 brea…

0301 basic medicineAbcg2DNA damageDNA repairCellneoplasmsergot alkaloids03 medical and health sciencesDopamine receptor D2AcromegalymedicinePharmacology (medical)Original ResearchbromocriptinepharmacogenomicsPharmacologydrug repurposingbiologybusiness.industrylcsh:RM1-950medicine.diseaseBromocriptinelcsh:Therapeutics. Pharmacology030104 developmental biologymedicine.anatomical_structureMitochondrial respiratory chainCancer researchbiology.proteinbusinessmedicine.drugFrontiers in Pharmacology
researchProduct

Lower-half facial migraine: a report of 11 cases.

2004

Purpose Vascular pain of the face constitutes a variant of pain of the head, and includes migraine, cluster headache, paroxysmal hemicrania, and a facial variant of the so-called lower-half migraine. Lower-half facial migraine is a condition difficult to classify; according to the international classifications it could not be found as an individual entity. The objective of the present study is to determine the difficulties we encountered in diagnosis, the ineffective treatments provided, and the pharmacologic treatment effect. Patients and methods A study is made of 11 cases of lower-half facial migraine, corresponding to 10 women and 1 man (mean age, 35 years), commenting on the clinical c…

AdultMalemedicine.medical_specialtyPediatricsMigraine DisordersIndomethacinCentral nervous system diseaseQuadrant (abdomen)Facial PainmedicineErgotamineMaxillaHumansParoxysmal HemicraniaVascular diseasebusiness.industryCluster headacheAnti-Inflammatory Agents Non-SteroidalAnalgesics Non-NarcoticMiddle Agedmedicine.diseaseLower halfSurgeryRoot Canal TherapyOtorhinolaryngologyMigraineTooth ExtractionErgotamineSurgeryFemaleOral Surgerybusinessmedicine.drugJournal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
researchProduct

Prevention of deep vein thrombosis in neurosurgical patients: a prospective double-blind comparison of two prophylactic regimen.

1992

In a prospective, randomized, double-blind investigation of anticoagulant agents for prevention of deep vein thrombosis in patients undergoing operations at the lumbar-vertebral disc, 179 patients were randomly allocated to two groups. 87 patients received a fixed combination of low-molecular weight heparin 1,500 U-aPTT plus dihydroergotamine 0.5 mg (LMWH/DHE) once a day and additionally one injection of placebo per day, 92 patients received a fixed combination of sodium heparin 5,000 U plus dihydroergotamine 0.5 mg (HDHE) twice a day. Treatment was initiated two hours preoperatively in both groups and continued for at least seven days. Deep vein thrombosis (DVT), detected by the 125Iodine-…

AdultMalemedicine.medical_specialtymedicine.drug_classDeep veinLow molecular weight heparinHemorrhageDihydroergotaminePostoperative ComplicationsDouble-Blind MethodRisk FactorsAntithromboticmedicineHumansProspective StudiesAgedLumbar Vertebraebusiness.industryHeparinAnticoagulantGeneral MedicineHeparinHeparin Low-Molecular-WeightMiddle AgedThrombophlebitismedicine.diseaseThrombosisSurgeryRegimenDrug Combinationsmedicine.anatomical_structureAnesthesiaSurgeryFemaleNeurology (clinical)businessDihydroergotamineIntervertebral Disc Displacementmedicine.drugNeurosurgical review
researchProduct

L'ergot dépasse le seigle cet ancien compagnon de l'homme ressort les griffes

2010

National audience; L’ergot du seigle dû à Claviceps purpurea se fait remarquer en cultures de céréales en France depuis 2000, sporadiquement et avec une prévalence moindre qu’en Europe du Nord. Le facteur climatique (4 années favorables de 2000 à 2009 incluses) joue sur cette réémergence, mais aussi des évolutions de pratiques culturales : développement du nonlabour et présence accrue de graminées adventices sensibles dans les parcelles ou à proximité. Les connaissances sur la biologie de C. purpurea et les facteurs le favorisant sont rappelées. Le rôle des graminées adventices et prairiales est évoqué avec les sensibilités diverses des espèces, pouvant influencer le choix de celles à impla…

BIOAGRESSEURS RE-EMERGEANTSINSECTEGRAMINEES ADVENTICESERGOT DE SEIGLE CLAVICEPS PURPUREA[SDV.BV.PEP] Life Sciences [q-bio]/Vegetal Biology/Phytopathology and phytopharmacy[SDV.BV.PEP]Life Sciences [q-bio]/Vegetal Biology/Phytopathology and phytopharmacyPOOIDEESPREVALENCE
researchProduct

Theoretical prediction of the chemiluminescence behaviour of the ergot alkaloids

2004

Abstract The present manuscript is dealing with the application of molecular connectivity calculations to predict the chemiluminescent behaviour of ergot alkaloids when they react with common strong oxidants in liquid phase. Twenty compounds were theoretically studied by means of a discriminant equation formerly published, being 19 of them predicted as chemiluminescent with a high probability. Empirical confirmation of the chemiluminometric behaviour is performed with the few soluble and commercially available ergot alkaloids. On the basis of these results, a new FIA-direct chemiluminescent method is proposed for the determination of the ergot presenting the higher light emission, the pharm…

Detection limitChromatographyAlkaloidRepeatabilityTartrateBiochemistryAnalytical Chemistrylaw.inventionchemistry.chemical_compoundchemistryErgotamine TartratelawErgotaminemedicineEnvironmental ChemistryOrganic chemistryLight emissionSpectroscopyChemiluminescencemedicine.drugAnalytica Chimica Acta
researchProduct

Adjuncts for ovarian stimulation: when do we adopt “orphan indications” for approved drugs?

2009

Several drugs, shown to be safe for other uses, have proven to be highly effective adjuncts for ovarian stimulation. The authors evaluate these "orphan" indications and make recommendations so that more patients will benefit from their use.

Drugendocrine systemmedicine.medical_specialtyOrphan Drug ProductionResearch methodologymedia_common.quotation_subjectFertilization in VitroReproductive technologyAcide acétylsalicyliqueHealth servicesProstaglandin-Endoperoxide SynthaseOvulation InductionHumansMedicineIntensive care medicinemedia_commonGynecologyAspirinHuman Growth Hormonebusiness.industryObstetrics and GynecologyErgot DerivativesEstrogensMetforminReproductive MedicineDopamine AgonistsAndrogensFemaleFertility agentsLeuprolidebusinessContraceptives OralPolycystic Ovary SyndromeFertility and Sterility
researchProduct

Influence of prebiotics, probiotics and protein ingredients on mycotoxin bioaccessibility

2015

The aim of this study was to investigate the influence of prebiotic compounds (cellulose and inulin), food ingredients (milk whey, β-lactoglobulin and calcium caseinate) and several probiotic microorganisms on the bioaccessibility of beauvericin (BEA), enniatins (ENs A, A1, B, B1), deoxynivalenol (DON) and zearalenone (ZEA) present in wheat crispy bread produced with wheat flour previously fermented with F. tricinctum, F. culmorum and G. zeae. The bioaccessibility of mycotoxins was determined by a dynamic simulated gastrointestinal digestion system, imitating the human digestive physiological conditions of the gastrointestinal tract. Mycotoxins were determined in the simulated intestinal fl…

Gibberellamedicine.medical_treatmentAntidotesFlourInulinBiological AvailabilityFood ContaminationModels BiologicalPoisonslaw.inventionchemistry.chemical_compoundProbioticFusariumlawmedicineHumansFood scienceMycotoxinZearalenonebiologyProbioticsPrebioticfood and beveragesBreadGeneral MedicineCalcium caseinateMycotoxinsGastrointestinal ContentsBeauvericinToxicokineticsGastrointestinal TractLactobacillusPrebioticsErgotismchemistryFermentationbiology.proteinDigestionBifidobacteriumDietary ProteinsDigestionFood ScienceFood & Function
researchProduct

Mikotoksīnu noteikšana kaķu barībā izmantojot AEŠH-MS/MS

2021

Mikotoksīnu noteikšana kaķu barībā izmantojot AEŠH-MS/MS. Maģistra darbs uzrakstīts latviešu valodā, tā apjoms ir 43 lappuses. Darbs satur 20 attēlus, 7 tabulas, 49 literatūras avotus, 7 pielikumus. Literatūras apskatā veikts novērtējums par ergota alkaloīdu un citu plašāk izplatīto mikotoksīnu klasifikāciju, to ietekmi uz cilvēku un dzīvnieku organismu. Apskatītas vairākas analīzes metodes mikotoksīnu noteikšanai, padziļināti izpētīta šķidruma hromatogrāfijas un masspektrometrijas metodes. Eksperimentālajā daļā veikta 20 sausās kaķu barības paraugu analīze, noteiktas 8 ergota alkaloīdu un 8 citu mikotoksīnu koncentrācijas. Paraugi analīze ir veikta, izmantojot AEŠH-MS/MS metodi.

Kaķu barībaErgota alkaloīdiMasspektrometrijaĶīmijaMikotoksīniHromatogrāfija
researchProduct

Cerebroarthrodigital syndrome: A newly recognized formal genesis syndrome in three patients with apparent arthromyodysplasia and sacral agenesis, bra…

1980

We describe three patients with a complex syndrome of apparent arthromyodysplasia, dyscephaly, sacral agenesis, and hypoplastic digitis. Cause is unknown, but an environmental cause is suspected on the basis of ergotamine exposure in one case and diazoxide intake in another, together with suggestive similarities to anomalies seen in animals treated with these drugs and to calves with the Australian hydranencephaly/arthrogryposis syndrome caused by Akebane or Aino virus. Pathogenetically the primary defect may be a neural tube-neural crest dysplasia with multiple secondary and tertiary manifestations and deformities.

Male2716 Genetics (clinical)medicine.medical_specialtyMicrocephalyPathology10039 Institute of Medical Genetics610 Medicine & healthHydranencephalySacral Agenesisaino virusarthromyodysplasia1311 GeneticsInternal medicineErgotaminemedicineHumansmicrocephalyNeural Tube Defectsformal genesis syndromeGenetics (clinical)ArthrogryposisArthrogryposisBone Diseases Developmentaldigital hypoplasiabusiness.industryDiazoxideInfant NewbornBrainakebane virusSyndromemedicine.diseaseHypoplasiahydrocephalyEndocrinology10036 Medical ClinicDysplasiaErgotamine570 Life sciences; biologyFemaleCrestsacral agenesismedicine.symptombusinessHydrocephalusmedicine.drugAmerican Journal of Medical Genetics
researchProduct

Clavine alkaloids and derivatives as mutagens detected in the Ames test.

1992

Eight cytostatic clavines were investigated for mutagenicity in Salmonella typhimurium (reversion of the his-strains TA98, TA100, TA102 and TA1537), directly and in the presence of a mammalian xenobiotic metabolizing system, S9 (NADPH-fortified postmitochondrial fraction of liver homogenate from Aroclor 1254-treated rats). Four compounds (festuclavine, 17-bromofestuclavine, 1-allylelymoclavine and 1-methyllysergol methyl ether) were direct mutagens, whose activity was enhanced in the presence of S9. The other compounds (1-cyclopentylfestuclavine, 13-bromo-1-cyclopropylmethylfestuclavine, 6-cyano-1-propyl-6-norfestuclavine and 6-allyl-1-propyl-6-norfestuclavine) showed mutagenic effects only…

MaleSalmonella typhimuriumCancer ResearchSalmonellaErgot AlkaloidsReversionEthermedicine.disease_causeAmes testRats Sprague-Dawleychemistry.chemical_compoundmedicineAgroclavineAnimalsPharmacology (medical)BiotransformationPharmacologychemistry.chemical_classificationMutagenicity Testsfood and beveragesAntimicrobialRatsEnzymeOncologyBiochemistrychemistryXenobioticMutagensAnti-cancer drugs
researchProduct